174 patents
Page 7 of 9
Utility
Methods of Shifting an Isoelectric Profile of a Protein Product and Uses Thereof
4 Mar 21
Provided herein are methods shifting the isoelectric profile of a recombinant protein product and the use of such methods in the manufacture of recombinant protein products.
Hunter F. MALANSON, Pratik JALURIA, Rachael ALFORD
Filed: 11 Jun 20
Utility
Compositions comprising an anti-C5 antibody
23 Feb 21
The present application relates to methods and compositions employing an antibody that inhibits activation of the complement system and can be used to prevent or treat a pulmonary disease or condition.
Yi Wang
Filed: 9 Oct 19
Utility
High Throughput Method for Measuring the Protease Activity of Complement C3 Convertase
28 Jan 21
Provided herein are high throughput methods for measuring the protease activity of the complement C3 convertase by detecting the consumption of C3 or the production of C3a in vivo and in vitro.
Christen D. FORBES
Filed: 21 Mar 19
Utility
Methods for treating hypophosphatasia in adolescents and adults
26 Jan 21
The disclosure features methods for treating hypophosphatasia (HPP) in a patient (e.g., adolescent or adult having HPP) exhibiting physical impairments or decreased walking ability by administering a soluble alkaline phosphatase (sALP) to the patient.
Kenji Fujita, Dawn Phillips, Agustin Melian
Filed: 31 Mar 17
Utility
Process for Preparation of Bis-Choline Tetrathiomolybdate
30 Dec 20
A process is provided for the production of bis-choline tetrathiomolybdate, the process comprising reacting a choline salt with ammonium tetrathiomolybdate, wherein the choline salt is a hydroxide, acetate, or halide choline salt, wherein the process comprises: combining the choline salt with a first mixture of ammonium tetrathiomolybdate in water, wherein a molar excess of choline salt to ammonium tetrathiomolybdate is used, for a first reaction period to provide a first reaction mixture; subjecting the first reaction mixture to a reduced pressure for a second reaction period to provide a second reaction mixture; and, isolating bis-choline tetrathiomolybdate from the second reaction mixture, wherein isolating bis-choline tetrathiomolybdate comprises adding ethanol to the second reaction mixture.
Johan Anders WENNERBERG, Hans Roger Marcus MÃ…RTENSSON
Filed: 14 Feb 19
Utility
Polypeptides That Bind Complement Component C5 or Serum Albumin and Fusion Proteins Thereof
23 Dec 20
The disclosure provides engineered polypeptides that specifically bind to human complement component C5 and/or serum albumin.
Bridget PUFFER, Julian CHANDLER, Nimish GERA, Douglas L. SHERIDAN, Siddharth JINDAL, Paul P. TAMBURINI
Filed: 10 Jul 18
Utility
Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients by an Inhibitor of Complement
16 Dec 20
Eculizumab, a humanized monoclonal antibody against C5 that inhibits terminal complement activation, showed activity in a preliminary 12-week open-label trial in a small cohort of patients with paroxysmal nocturnal hemoglohinuria (PNH).
Leonard BELL, Russell P. ROTHER, Mark J. EVANS
Filed: 22 Jan 20
Utility
Solid forms of cerdulatinib
14 Dec 20
Forms of cerdulatinib and salts or co-crystals thereof were prepared and characterized in the solid state.
Anjali Pandey, Julian Scott Northen, Philippe Fernandes, Ying Chen, Yuelie Lu, Sami Karaborni, Gus Kodersha
Filed: 2 May 19
Utility
Lysosomal storage disease enzymes
7 Dec 20
The present invention provides compositions of recombinant human lysosomal acid lipase having particular glycosylation patterns for internalization into target cells, a vector containing the nucleic acid encoding human lysosomal acid lipase, a host cell transformed with the vector, pharmaceutical compositions comprising the recombinant human lysosomal acid lipase and method of treating conditions associated with lysosomal acid lipase deficiency.
Anthony Quinn, Alex J. Harvey
Filed: 8 Jul 19
Utility
High Concentration ANTI-C5 Antibody Formulations
25 Nov 20
The present disclosure relates to stable aqueous solutions comprising a high concentration of an anti-C5 antibody (e.g., ravulizumab) and methods for preparing the solutions.
Stephan ORTIZ, Jillian GENTILE, Leena PHILOMINATHAN, Eric ROUTHIER, Bruce MASON
Filed: 26 Jul 18
Utility
Compositions and methods for treating craniosynostosis
2 Nov 20
Provided herein are compositions and methods for treating craniosynostosis.
Nan Hatch
Filed: 9 Jul 15
Utility
Dosage and Administration of ANTI-C5 Antibodies for Treatment of Generalized Myasthenia Gravis
21 Oct 20
Provided are methods for clinical treatment of generalized myasthenia gravis (gMG) using an anti-C5 antibody or antigen binding fragment thereof.
Kenji Fujita, Nishi Rampal, Wei-Jian Pan, Kaushik Patra
Filed: 13 Feb 20
Utility
Methods of Treating Myointimal Proliferation
30 Sep 20
The present invention provides a method of treating myointimal proliferation by administering a recombinant human soluble ectonucleotide pyrophosphatase phosphodiesterase (hsNPP1), active fragment or fusion protein thereof.
Yan YAN, Anumeha SHAH, Ashmita SAIGAL, Herman GRIFFIN, Susan Faas MCKNIGHT, Andre MAROZSAN, Kim ASKEW, Yvonne NITSCHKE, Frank RUTSCH
Filed: 14 Jun 17
Utility
Methods for Treating Hypophosphatasia In Children and Adolescents
30 Sep 20
The disclosure features methods for treating hypophosphatasia (HPP) in a patient (e.g., a child or an adolescent having HPP) exhibiting gait impairments or decreased walking ability by administering a soluble alkaline phosphatase (sALP) to the patient and assessing improvement in the gait impairment using a modified Performance-Oriented Mobility Assessment-Gait (mPOMA-G) analysis and score.
Kenji FUJITA, Marc VALLEE, Dawn PHILLIPS
Filed: 26 Jun 16
Utility
Methods of Improving Cardiovascular Function and Treating Cardiovascular Disease Using a Recombinant Ectonucleotide Pyrophosphatase Phosphodiesterase (NPP1)
19 Aug 20
The present invention provides methods for improving cardiovascular function in a human patient (e.g., reducing hypertension), as well as methods of treating a cardiovascular disease, by administering a recombinant human soluble ectonucleotide pyrophosphatase phosphodiesterase (hsNPP1), active fragment or fusion protein thereof.
Tayeba KHAN, Andre MAROZSAN, Kim ASKEW
Filed: 25 Sep 18
Utility
Dosage and Administration of ANTI-C5 Antibodies for Treatment of Patients with Membranoproliferative Glomerulonephritis
19 Aug 20
Provided are methods for clinical treatment of Membranoproliferative glomerulonephritis (MPGN) by administering an anti-C5 antibody, or antigen binding fragment thereof.
Giuseppe REMUZZI, Piero RUGGENENTI, Xiang GAO
Filed: 1 Oct 18
Utility
Dosage and Administration of ANTI-C5 Antibodies for Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (Ahus)
12 Aug 20
Provided are methods for clinical treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS) using an anti-C5 antibody, or antigen binding fragment thereof.
Lori PAYTON, Scott T. ROTTINGHAUS, Rajendra PRADHAN, Andrew DAMOKOSH, Xiang GAO
Filed: 25 Oct 18
Utility
Biomarker Signature for Predicting Tumor Response to ANTI-CD200 Therapy
22 Jul 20
Provided herein are methods for treating cancer in a patient who has been determined to have positive expression of CD200 receptor (CD200R1) and one or more biomarkers (i.e., ICOS, TIGIT, TNFRSF9, HAVCR2, PDCD1, FCGR2A, FCGR1A, CD163, and/or CD14) by administering to the patient a CD200 inhibitor.
Rui-Ru JI, Mark HAMILTON, Sharon BARR
Filed: 25 Sep 18
Utility
Metal Impact on Manufacturing of Alkaline Phosphatases
15 Jul 20
The disclosure provides a method of producing recombinant alkaline phosphatase comprising: (i) culturing an alkaline phosphatase in a recombinant cell culture; (ii) obtaining a preparation of recombinant alkaline phosphatase from the cell culture; and (iii) minimizing in the preparation a concentration of at least one metal ion selected from the group consisting of: Nickel (Ni), Cobalt (Co), Copper (Cu), Manganese (Mn), Chromium (Cr), and Molybdenum (Mo).
Saravanamoorthy RAJENDRAN, Rachael ALFORD, Sean GALLAGHER, Anne KANTARDJIEFF, Jared DAVIS
Filed: 5 Jun 17
Utility
Methods of shifting an isoelectric profile of a protein product and uses thereof
13 Jul 20
Provided herein are methods shifting the isoelectric profile of a recombinant protein product and the use of such methods in the manufacture of recombinant protein products.
Hunter F. Malanson, Pratik Jaluria, Rachael Alford
Filed: 18 Jan 18